Recursion Pharmaceuticals ( (RXRX) ) just unveiled an announcement.
Recursion Pharmaceuticals, Inc. has announced FDA clearance for the clinical trial of REC-1245, a groundbreaking RBM39 degrader aimed at treating biomarker-enriched solid tumors and lymphoma. Leveraging AI and machine learning, Recursion has rapidly transformed REC-1245 from a novel concept to a preclinical drug candidate in less than 18 months, significantly outpacing industry norms. With the potential to serve over 100,000 patients in the US and EU5, REC-1245 is poised to offer new hope for those with limited treatment options, with Phase 1/2 clinical trials set to begin in the fourth quarter of 2024.
Find detailed analytics on RXRX stock on TipRanks’ Stock Analysis page.